Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-08-14

FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

Supplemental application for Alecensa (alectinib hydrobromide) submitted by Genentech, Inc. for regulatory action related to an approved indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alecensa (alectinib)

Snippet

SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)